Therapeutic optimism in the consent forms of phase 1 gene transfer trials: An empirical analysis

Journal of Medical Ethics

Volumn 31, Issue 4, 2005, Pages 209-214

  Kimmelman, Jonathan ^a   Palmour, N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; NEW DRUG; TNFERADE; TUMOR NECROSIS FACTOR; VACCINE;

ANALYTIC METHOD; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMPIRICAL RESEARCH; EXPERIMENTATION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HUMAN; INFORMED CONSENT; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; NOMENCLATURE; SOCIAL ASPECT; STATISTICAL SIGNIFICANCE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH; GENETICS AND REPRODUCTION;

CLINICAL TRIALS, PHASE I; COMPREHENSION; CONSENT FORMS; ETHICS, CLINICAL; ETHICS, RESEARCH; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INFORMED CONSENT; NONTHERAPEUTIC HUMAN EXPERIMENTATION; PATIENT EDUCATION; RISK ASSESSMENT; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 17444390889     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2003.006247     Document Type: Article

References (29)

1. Appelbaum PS, Roth LH, Lidz CW, et al. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;17:20-4.
2. Howard J, Friedman L. Protecting the scientific integrity of a clinical trial: Some ethical dilemmas. Clin Pharmacol Ther 1981;29:561-69.
3. Lidz CW, Appelbaum PS. The therapeutic misconception: problems and solutions. Med Care 2002;40(Suppl 9):V55-63.
4. Miller M. Phase 1 cancer trials: a collusion of misunderstanding. Hastings Cent Rep 2000;30:34-42.
5. Levine, RJ. Ethics of clinical trials: do they help the pafient? Cancer 1993;72:2805-10.
6. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase i trials. J Clin Oncol 1995;13:1062-72.
7. Schaeffer MH, Krantz DS, Wichman A, et al. The impact of disease severity on the informed consent process in clinical research. Am J Med 1996;100:261-8.
8. Joffe S, Cook EF, Cleary PD, et al. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 2001;358:1772-7.
9. Penman DT, Holland JC, Bahna GF, et al. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol 1984;2:849-55.
10. Madsen SM, Mirza MR, Holm S, et al. Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med 2002;251:156-68.
11. Churchill LR, Collins ML, King NMP, et al. Genetic research as therapy: implications of "gene therapy" for informed consent. J Law Med Ethics 1998;26:38-47.
12. Neuendorf KA. The content analysis guidebook. Thousand Oaks, CA: Sage, 2002.
13. Human Gene Transfer Protocols. Available at http://www4.od.nih.gov/oba/rac/clinicaltrial.htm (accessed 16 July 2003).
14. Juengst ET, Walters L. Ethical issues in human gene transfer research. In: Friedmann T, ed. The development of human gene therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999:691-712.
15. King NM. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 2000;28:332-43.
16. Levine RJ. The impact of HIV infection on society's perception of clinical trials. Kennedy Inst Ethics J 1994;4 93-8.
17. American Society of Clinical Oncology. Critical role of phase 1 clinical trials in cancer treatment. J Clin Oncol 1997; 15:853-9.
18. Lipsett MB. On the nature and ethics of phase 1 clinical trials of cancer chemotherapies. JAMA 1982;248 941-2.
19. Estey E, Hoth D, Simon R, et al. Therapeutic response in phase 1 trials of antineoplastic agents. Cancer Treat Rep 1986;70:1105-15.
20. Decoster G, Stein G, Holdener EE. Response and toxic deaths in phase 1 clinical trials. J Ann Oncol 1990; 2:175-81.
21. Von Hoff DD, Turner J. Response rates, duration of response and dose response effect in phase 1 studies in antineoplastics. Invest New Drugs 1991;9:115-22.
22. Kodish E, Stocking C, Ratain MJ, et al. Ethical issues in phase 1 oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol 1992; 10 1810-16.
23. Sugarman J, Kass NE, Goodman SN, et al. What patients say about medical research. IRB 1998;20:1-7.
24. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med 1997; 45 1337-55.
25. Kent G. Shared understanding for informed consent: the relevance of psychological research on the provision of information. Soc Sci Med 1996;43:1517-23.
26. Horng S, Emanuel EJ, Wilfond B, et al. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 2002;347:2134-40.
27. Orkin SH, Motulsky AG. National Institutes of Health Ad Hoc Committee Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. 7 December 1995. Available at http://www4.od.nih.gov/oba/rac/panelrephtm (accessed 12 June 2003).
28. Levinsky NG. Nonfinancial conflicts of interest in research. N Engl J Med 2002;347:759-61.
29. King NMP. Experimental treatment: oxymoron or aspiration? Hastings Cent Rep 1995;25:6-15.